2BO.F Serina Therapeutics, Inc.
- Market cap
- EUR 31.2M
- P/E
- -
- P/B
- 1.86x
- ROE
- -141.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 2BO.F undervalued?
Graham numberThe Graham number of Serina Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Serina Therapeutics, Inc. fundamental analysis
No fundamental analysis for Serina Therapeutics, Inc. yet.
Serina Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg …
Full company profileSerina Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Serina Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 3.46M | 500K | 3.00M | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.63M | -2.27M | -3.13M | -17.0M | -24.0M | -26.1M |
| EBITDA | - | -2.60M | 5.92M | -10.5M | -18.9M | -25.6M |
| Net Income | -1.26M | -2.68M | 5.27M | -11.1M | -19.2M | -26.5M |
| EPS | -0.15 | -0.32 | 0.63 | -1.18 | -1.78 | -1.77 |
| Balance Sheet | ||||||
| Total Assets | 1.84M | 858K | 8.97M | 6.72M | 6.95M | 25.8M |
| Total Liabilities | 37.0M | 38.6M | 41.3M | 6.22M | 6.99M | 7.08M |
| Shareholders' Equity | -35.1M | -37.8M | -32.3M | 641K | -37.0K | 18.7M |
| Cash & Short-term Investments | 315K | 532K | 7.62M | 3.67M | 3.06M | 23.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -2.25M | -2.08M | -2.48M | -17.1M | -18.0M | -22.5M |
| Capital Expenditure | 108K | 9.68K | 504K | 22.0K | 59.0K | 106K |
| Free Cash Flow | -2.36M | -2.09M | -2.98M | -17.2M | -18.0M | -22.6M |
| Ratios | ||||||
| ROE | - | - | - | -1,738.1% | - | -141.5% |
| ROA | -68.6% | -312.6% | 58.8% | -165.7% | -276.0% | -102.7% |
| Net Profit Margin | -36.5% | -536.4% | 175.6% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Serina Therapeutics, Inc. dividends
Serina Therapeutics, Inc. has not paid dividends in the last 5 fiscal years.
Who owns Serina Therapeutics, Inc.
- Insiders 50.76%
- Institutions 9.78%
- Public & others 39.46%
- Shares outstanding 25.4M
- Free float 9.15M
Serina Therapeutics, Inc. company profile
- Company name
- Serina Therapeutics, Inc.
- Ticker
- 2BO.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Fiscal year end
- December
- Address
- 601 Genome Way, Huntsville, AL, United States, 35806
- Phone
- 256 327 9630
- Website
- serinatx.com
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Serina Therapeutics, Inc. management
7- Dr. Balkrishan Gill Ph.D.Executive Co-Chairman of the Board · born 1965
- Mr. Steven A. LedgerCEO & Director · born 1959
- Dr. J. Milton Harris Ph.D.Co-Founder, Director Emeritus & Chair of Scientific Advisory Board · born 1941
- Dr. Srini Tenjarla Ph.D.Chief Technical Operations Officer · born 1962
- Dr. Randall W. Moreadith M.D., Ph.D.Chief Development Officer · born 1955
- Mr. Gregory S. CurhanChief Financial Officer · born 1962
- Dr. Joshua Thomas Ph.D.Head of Chemistry